Liu Tony 5

Accession 0001654954-20-001538

CIK 0001378624other

View on SEC.gov Company Profile

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 5:20 PM ET

Size

45.6 KB

Accession

0001654954-20-001538

Insider Transaction Report

Form 5

Period: 2019-12-31

Cellular Biomedicine Group, Inc.CBMG

Liu Tony

Director

Transactions

Sale
Common Stock
2019-01-25$17.69/sh−875$15,479→ 255,392 total
Sale
Common Stock
2019-02-27$18.06/sh−875$15,802→ 254,517 total
Sale
Common Stock
2019-03-27$16.80/sh−875$14,700→ 253,642 total
Sale
Common Stock
2019-04-29$16.89/sh−875$14,779→ 252,767 total
Sale
Common Stock
2019-05-28$16.94/sh−875$14,823→ 251,892 total
Sale
Common Stock
2019-06-27$14.94/sh−875$13,073→ 251,017 total
Sale
Common Stock
2019-07-29$13.70/sh−875$11,988→ 250,142 total
Sale
Common Stock
2019-08-27$11.47/sh−875$10,036→ 249,267 total
Sale
Common Stock
2019-09-27$14.68/sh−875$12,845→ 248,392 total
Sale
Common Stock
2019-10-28$15.08/sh−875$13,195→ 247,517 total
Award
Employee Stock Option (Right to Buy)
2015-04-06+30,000→ 30,000 total
Exercise: $35.53Exp: 2025-04-06→ Common Stock (30,000 underlying)
Award
Employee Stock Option (Right to Buy)
2016-01-23+13,000→ 13,000 total
Exercise: $40.00Exp: 2026-01-23→ Common Stock (13,000 underlying)
Award
Employee Stock Option (Right to Buy)
2016-04-11+40,000→ 40,000 total
Exercise: $20.00Exp: 2026-04-11→ Common Stock (40,000 underlying)
Other
Employee Stock Option (Right to Buy)
2017-05-14−13,000→ 0 total
Exercise: $40.00Exp: 2026-01-23→ Common Stock (13,000 underlying)

Holdings

Employee Stock Option (Right to Buy)
Exercise: $7.23Exp: 2023-03-05→ Common Stock (5,300 underlying)
5,300
Employee Stock Option (Right to Buy)
Exercise: $5.00Exp: 2024-01-03→ Common Stock (255,000 underlying)
255,000
Employee Stock Option (Right to Buy)
Exercise: $20.63Exp: 2021-07-23→ Common Stock (15,000 underlying)
15,000
Employee Stock Option (Right to Buy)
Exercise: $20.63Exp: 2021-08-14→ Common Stock (15,000 underlying)
15,000
Employee Stock Option (Right to Buy)
Exercise: $15.53Exp: 2021-12-31→ Common Stock (105,800 underlying)
105,800
Employee Stock Option (Right to Buy)
Exercise: $12.55From: 2017-01-21Exp: 2027-01-21→ Common Stock (30,000 underlying)
30,000
Employee Stock Option (Right to Buy)
Exercise: $12.40Exp: 2027-03-03→ Common Stock (120,000 underlying)
120,000

Footnotes (27)

[F1]As previously reported on the Reporting Person's Form 4 filed on April 3, 2017, on March 27, 2017, the Reporting Person was granted 120,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G1) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan (the "Plan"), which RSUs vest according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
[F10]On September 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.68. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F11]On October 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $15.08. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F12]Due to administrative errors, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year was inaccurately reported in Column 5 of Table I of the Reporting Person's Form 5 filed on February 14, 2019 (the "2019 Form 5") and prior Section 16 reports. As a result, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year in Column 5 of Table I of this form does not correspond with the number reported in the 2019 Form 5. This form corrects the prior reporting and rounding errors made in Column 5 of Table I of the Reporting Person's prior Section 16 reports.
[F13]In the Reporting Person's prior Section 16 reports, employee stock options were referred to using various differing titles. For convenience, in the Reporting Person's future Section 16 reports, all employee stock options to buy common stock will be referred to using the title "Employee Stock Option (Right to Buy)." The nature and economic terms of the re titled employee stock options remain unchanged.
[F14]These derivatives securities were cancelled on May 14, 2017 and the Reporting Person received no value in connection with this cancellation.
[F15]As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on July 29, 2016, on April 6, 2015, the Reporting Person was granted an employee stock option to purchase up to 30,000 shares of common stock, of which 9,000 shares vested and became fully exercisable on April 6, 2016; 9,000 shares vested and became fully exercisable on April 6, 2017; and 12,000 shares vested and became fully exercisable on April 6, 2018.
[F16]As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on January 23, 2016, the Reporting Person was granted an employee stock option to purchase up to 13,000 shares of common stock, of which 3,900 shares vested and became fully exercisable on January 23, 2017; 3,900 shares vested and became fully exercisable on January 23, 2018; and 5,200 shares vested and became fully exercisable on January 23, 2019.
[F17]As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on April 11, 2016, the Reporting Person was granted an employee stock option to purchase up to 40,000 shares of common stock, of which 12,000 shares vested and became fully exercisable on April 11, 2017; 12,000 shares vested and became fully exercisable on April 11, 2018; and 16,000 shares vested and became fully exercisable on April 11, 2019.
[F18]This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of March 5, 2013.
[F19]This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of January 3, 2014.
[F2]On January 25, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $17.69. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F20]This option vested over a period of three years according to the following schedule: 1/3 on July 23, 2015 and 1/3 on each anniversary thereafter.
[F21]This option vested over a period of three years according to the following schedule: 1/3 on August 14, 2015 and 1/3 on each anniversary thereafter.
[F22]This option vested over a period of three years according to the following schedule: 1/3 on December 31, 2015 and 1/3 on each anniversary thereafter.
[F23]This option (Grant No. 14-324) vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
[F24]The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 27, 2014. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.
[F25]The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 13, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.
[F26]The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 17, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.
[F27]The acquisition of these derivative securities was previously reported on the Reporting Person's Form 4 filed on April 3, 2017. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.
[F3]On February 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $18.06. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F4]On March 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.80. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F5]On April 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.89. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F6]On May 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F7]On June 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F8]On July 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $13.70. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
[F9]On August 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $11.47. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.

Documents

1 file

5
section16.xmlPrimary
PRIMARY DOCUMENT

Issuer

Cellular Biomedicine Group, Inc.

CIK 0001378624

→

Entity typeother

Related Parties

filerCIK 0001569983

Filing Metadata

Form type: 5
Filed: Feb 12, 7:00 PM ET
Accepted: Feb 13, 5:20 PM ET
Size: 45.6 KB

View on SEC.gov